The development of type-1 autoimmune hepatitis after chronic hepatitis C (HCV) clearance by direct-acting antivirals (DAA)

Rev Esp Enferm Dig. 2020 Aug;112(8):664-665. doi: 10.17235/reed.2020.6785/2019.

Abstract

We present the case of a 72-year-old female in follow-up for chronic hepatitis due to hepatitis C virus (HCV) genotype 1b, with a liver stiffness measurement estimated by transient elastography in 2015 of 17 Kp and type 2 diabetes mellitus. She was treated daily with ledipasvir 90 mg and sofosbuvir 400 mg for 12 weeks. In March 2016, she achieved a sustained virological response (SVR) after 12 weeks and 24 weeks. She had a positive determination of antinuclear antibodies 7.9 in 2014.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antiviral Agents / therapeutic use
  • Diabetes Mellitus, Type 2* / drug therapy
  • Drug Therapy, Combination
  • Female
  • Genotype
  • Hepacivirus / genetics
  • Hepatitis C, Chronic* / complications
  • Hepatitis C, Chronic* / drug therapy
  • Hepatitis, Autoimmune* / drug therapy
  • Hepatitis, Autoimmune* / etiology
  • Humans
  • Treatment Outcome

Substances

  • Antiviral Agents